Clinical Trial Update: Study of TRU-015 in Subjects With Membranous Nephropathy Secondary to Systemic Lupus Erythematosus [Phase 1]

View source ↗

Summary

Phase 1 study of TRU-015 for membranous nephropathy secondary to systemic lupus erythematosus was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Membranous Nephropathy
• Systemic Lupus Erythematosus

Drugs mentioned

• TRU-015

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Systemic Lupus Erythematosus | Phase 1 | Status: TERMINATED